Comparison of Multi-Gene Testing Data Between Fresh and Formalin-Fixed Specimens From Core Needle Biopsy in Patients With NSCLC

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 2022 Jan 3

PMID 34975346

Authors

Zhi-Gang Yao

Zhi-Gang Wei

Xian-Kui Cheng

Guang-Hui Huang

Yuan-Yuan Zong

Min Meng

Jia-Mei Li

Xiao-Ying Han

Jia-Wen Xu

Jiao Wang

Hai-Yan Jing

Wen-Hong Li

Zhi-Xin Cao

Yang Ni

Xi-Chao Sun

Xia Yang

Xin Ye

Affiliations

Soon will be listed here.

Abstract

Currently, formalin-fixed paraffin-embedded (FFPE) tissue specimens are the conventional material for gene testing for non-small cell lung cancer (NSCLC) patients. In our study, we aimed to develop a quick gene testing procedure using fresh core needle biopsy samples from NSCLC patients. In total, 77 fresh NSCLC samples obtained from core needle biopsy were evaluated by frozen section examination. If the NSCLC diagnosis and adequate tumor cell counts were confirmed by histopathology, the fresh tissues were used to extract DNA and subsequent gene testing by ARMS-PCR. Meanwhile, the paired FFPE core needle biopsy samples from 30 NSCLC patients also underwent gene testing. In total, 77 fresh samples showed an EGFR mutation rate of 61.0%, higher than the levels in the Asian. Following a comparison of gene testing results with fresh tissues and paired FFPE tissues from the 30 patients, no significant difference in the DNA concentration extracted from fresh tissues and FFPE tissues was found. However, DNA purity was significantly higher in fresh tissues than that in FFPE tissues. Gene testing detected the same gene mutations in 93.3% of cases in fresh tissues and paired FFPE tissues. The gene testing procedure using fresh biopsy samples greatly shortens the waiting time of patients. The multi-gene mutation testing using fresh core needle biopsy samples from NSCLC patients is a reasonable, achievable, and quick approach. Fresh tissues may serve as a potential alternative to FFPE tissues for gene testing in NSCLC patients.

References

Wu S, Shi X, Si X, Liu Y, Lu T, Zhang L . EGFR T790M detection in formalin-fixed paraffin-embedded tissues of patients with lung cancer using RNA-based in situ hybridization: A preliminary feasibility study. Thorac Cancer. 2019; 10(10):1936-1944. PMC: 6775006. DOI: 10.1111/1759-7714.13169. View

Lai Y, Zhang Z, Li J, Sun D, Zhou Y, Jiang T . EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. Int J Mol Sci. 2013; 14(12):24549-59. PMC: 3876127. DOI: 10.3390/ijms141224549. View

Chen C, Chang J, Cheung Y, Lin G, Hsieh J, Hsu T . Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer. Acta Radiol. 2008; 49(9):991-4. DOI: 10.1080/02841850802294410. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Ulivi P, Romagnoli M, Chiadini E, Casoni G, Capelli L, Gurioli C . Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. Int J Oncol. 2012; 41(1):147-52. DOI: 10.3892/ijo.2012.1432. View

Sheinson D, Wong W, Wu N, Mansfield A . Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer. Lung Cancer. 2020; 143:86-92. DOI: 10.1016/j.lungcan.2020.03.005. View

Zhang C, Schmidt L, Hatanaka K, Thomas D, Lagstein A, Myers J . Evaluation of napsin A, TTF-1, p63, p40, and CK5/6 immunohistochemical stains in pulmonary neuroendocrine tumors. Am J Clin Pathol. 2014; 142(3):320-4. DOI: 10.1309/AJCPGA0IUA8BHQEZ. View

Wang J, Ni Y, Yang X, Huang G, Wei Z, Li W . Diagnostic ability of percutaneous core biopsy immediately after microwave ablation for lung ground-glass opacity. J Cancer Res Ther. 2019; 15(4):755-759. DOI: 10.4103/jcrt.JCRT_399_19. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

10.

Marino F, Bianco R, Accardo M, Ronchi A, Cozzolino I, Morgillo F . Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. Int J Med Sci. 2019; 16(7):981-989. PMC: 6643125. DOI: 10.7150/ijms.34739. View

11.

Verhoest G, Patard J, Fergelot P, Jouan F, Zerrouki S, Dreano S . Paraffin-embedded tissue is less accurate than frozen section analysis for determining VHL mutational status in sporadic renal cell carcinoma. Urol Oncol. 2010; 30(4):469-75. DOI: 10.1016/j.urolonc.2010.07.005. View

12.

Suciu B, Pap Z, Denes L, Brinzaniuc K, Copotoiu C, Pavai Z . Allele-specific PCR method for identification of EGFR mutations in non-small cell lung cancer: formalin-fixed paraffin-embedded tissue versus fresh tissue. Rom J Morphol Embryol. 2016; 57(2):495-500. View

13.

Matsumura M, Okudela K, Kojima Y, Umeda S, Tateishi Y, Sekine A . A Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential - An Implication of Micropapillary Element. PLoS One. 2016; 11(11):e0166795. PMC: 5115808. DOI: 10.1371/journal.pone.0166795. View

14.

Spencer D, Sehn J, Abel H, Watson M, Pfeifer J, Duncavage E . Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J Mol Diagn. 2013; 15(5):623-33. PMC: 4912568. DOI: 10.1016/j.jmoldx.2013.05.004. View

15.

Cheung Y, Chang J, Hsieh J, Lin G, Tsai Y . Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle. Lung Cancer. 2009; 67(2):166-9. DOI: 10.1016/j.lungcan.2009.04.007. View

16.

Shi Y, Au J, Thongprasert S, Srinivasan S, Tsai C, Khoa M . A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9(2):154-62. PMC: 4132036. DOI: 10.1097/JTO.0000000000000033. View

17.

. [The Guideline for Diagnosis and Treatment of Chinese Patients with sensitizing EGFR Mutation or ALK Fusion Gene-Positive Non-Small Cell Lung Cancer (2015 Version)]. Zhonghua Zhong Liu Za Zhi. 2016; 37(10):796-9. View

18.

Zhou C . Lung cancer molecular epidemiology in China: recent trends. Transl Lung Cancer Res. 2015; 3(5):270-9. PMC: 4367759. DOI: 10.3978/j.issn.2218-6751.2014.09.01. View

19.

Shi Y, Li J, Zhang S, Wang M, Yang S, Li N . Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. PLoS One. 2015; 10(11):e0143515. PMC: 4657882. DOI: 10.1371/journal.pone.0143515. View

20.

Wu F, Wang L, Zhou C . Lung cancer in China: current and prospect. Curr Opin Oncol. 2020; 33(1):40-46. DOI: 10.1097/CCO.0000000000000703. View